CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
The plant is scheduled to come on stream in September 2024
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Subscribe To Our Newsletter & Stay Updated
